{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:24:36Z","timestamp":1788834276471,"version":"build-2803163510"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.critrevonc.2020.103096","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T12:05:58Z","timestamp":1601294758000},"page":"103096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy"],"prefix":"10.1016","volume":"157","author":[{"given":"Stella","family":"Bouziana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Bouzianas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2020.103096_bib0005","first-page":"36","article-title":"Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","author":"Abramson","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103096_bib0010","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0015","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103096_bib0020","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The european medicines agency review of kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-Cell lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0025","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2020.103096_bib0030","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2019-123424","article-title":"Phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-Cell therapy targeting CD19 and CD22, in pediatric patients with Relapsed\/Refractory B-Cell acute lymphoblastic leukemia (r\/r B-ALL): amelia study","volume":"134","author":"Amrolia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0035","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","article-title":"T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells","volume":"128","author":"Azzaoui","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0040","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMp1807382","article-title":"National coverage analysis of CAR-T therapies \u2014 policy, evidence, and payment","volume":"379","author":"Bach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/bio.2016.0119","article-title":"Integrating molecular control to improve cryopreservation outcome","volume":"15","author":"Baust","year":"2017","journal-title":"Biopreserv. Biobank."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2020.103096_bib0050","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic Anti-CD19 CAR T-Cell product, in a pool of adult and pediatric patients with high-risk CD19+ Relapsed\/Refractory B-Cell acute lymphoblastic leukemia","volume":"132","author":"Benjamin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0055","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00262-018-2155-7","article-title":"Induction of a central memory and stem cell memory phenotype in functionally active CD4(+) and CD8(+) CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19(+) acute lymphoblastic leukemia","volume":"67","author":"Blaeschke","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0060","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3389\/fimmu.2017.01221","article-title":"PI3Kdelta inhibition enhances the antitumor fitness of adoptively transferred CD8+ t cells","volume":"8","author":"Bowers","year":"2017","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.critrevonc.2020.103096_bib0065","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1182\/blood.V126.23.3100.3100","article-title":"Successful translation of chimeric antigen receptor (CAR) targeting CD19 (CTL019) cell processing technology from academia to industry","volume":"126","author":"Boyd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V128.22.999.999","article-title":"T cells expressing a novel fully-human anti-CD19 chimeric antigen receptor induce remissions of advanced lymphoma in a first-in-humans clinical trial","volume":"128","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0080","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103096_bib0085","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1097\/HS9.0000000000000188","article-title":"CAR-t cells: future perspectives","volume":"3","author":"Charrot","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0090","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103096_bib0095","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2020.103096_bib0100","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/1538-7445.AM2018-1630","article-title":"FLT3 chimeric antigen receptor T cell therapy induces B to T cell lineage switch in infant acute lymphoblastic leukemia","volume":"78","author":"Chien","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0105","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","article-title":"Sequential Anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-hodgkin lymphomas","volume":"132","author":"Chong","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.critrevonc.2020.103096_bib0110","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.2019002258","article-title":"CAR T cell viability release testing and clinical outcomes: is there a lower limit?","volume":"134","author":"Chong","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0115","article-title":"How to train your t cells: overcoming immune dysfunction in multiple myeloma","author":"Cohen","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.critrevonc.2020.103096_bib0120","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0125","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1002\/ajh.25416","article-title":"CARs of the future","volume":"94","author":"Daniyan","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2020.103096_bib0130","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1158\/1538-7445.AM2018-1631","article-title":"T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential","volume":"78","author":"Das","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0135","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103096_bib0140","first-page":"382","article-title":"Role of CD8 t cell replicative senescence in human aging and in HIV-mediated immunosenescence","volume":"2","author":"Dock","year":"2011","journal-title":"Aging Dis."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0145","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the g or z subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0150","series-title":"Committee for Medicinal Products for Human Use","author":"European Medicines Agency","year":"2018"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0155","series-title":"Committee for Medicinal Products for Human Use","author":"European Medicines Agency","year":"2018"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103096_bib0165","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41590-019-0452-8","article-title":"At the end of the beginning: immunotherapies as living drugs","volume":"20","author":"Feigal","year":"2019","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103096_bib0170","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0195","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"Suppl_1","key":"10.1016\/j.critrevonc.2020.103096_bib0200","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2018-99-117493","article-title":"Starting T cell and cell product phenotype are associated with durable remission of leukemia following CD19 CAR-T cell immunotherapy","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0205","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2018-99-113126","article-title":"Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0210","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","article-title":"Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes","volume":"64","author":"Garnett","year":"2004","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103096_bib0215","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0220","doi-asserted-by":"crossref","first-page":"9728","DOI":"10.18632\/oncotarget.23887","article-title":"Cell banking for regulatory T cell-based therapy: strategies to overcome the impact of cryopreservation on the Treg viability and phenotype","volume":"9","author":"Golab","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0225","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.bbmt.2017.01.018","article-title":"Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with B-cell Non-Hodgkin lymphoma (B-NHL): reversal of toxicity from tonic signaling","volume":"23","author":"Gomes da Silva","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"10","key":"10.1016\/j.critrevonc.2020.103096_bib0230","doi-asserted-by":"crossref","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"issue":"7750","key":"10.1016\/j.critrevonc.2020.103096_bib0235","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0240","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0245","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2020.103096_bib0250","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma patients treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0255","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","article-title":"Differences in expansion potential of naive chimeric antigen receptor t cells from healthy donors and untreated chronic lymphocytic leukemia patients","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0260","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1097\/HS9.0000000000000172","article-title":"CAR T cells: a snapshot on the growing options to design a CAR","volume":"3","author":"Holzinger","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0265","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2018-99-110142","article-title":"Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies","volume":"132","author":"Hossain","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103096_bib0270","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-018-0164-6","article-title":"The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL","volume":"9","author":"Hucks","year":"2019","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103096_bib0275","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/14712598.2019.1614164","article-title":"Novel approaches to promote CAR T-cell function in solid tumors","volume":"19","author":"Hull","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2020.103096_bib0280","doi-asserted-by":"crossref","first-page":"92a","DOI":"10.1182\/blood-2018-99-117199","article-title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0285","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat. Commun."},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2020.103096_bib0290","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1182\/blood-2019-129120","article-title":"Portia: a phase 1b study evaluating safety and efficacy of Tisagenlecleucel and Pembrolizumab in patients with Relapsed\/Refractory diffuse large B-Cell lymphoma","volume":"134","author":"Jaeger","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0295","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fphar.2014.00254","article-title":"Improving the safety of cell therapy products by suicide gene transfer","volume":"5","author":"Jones","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0300","doi-asserted-by":"crossref","first-page":"39833","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive selfdecision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0305","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103096_bib0310","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00262-014-1568-1","article-title":"Engineered T cells for cancer therapy","volume":"63","author":"June","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103096_bib0315","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"Clinical utilization of chimeric antigen receptor t cells in B cell acute lymphoblastic leukemia: an expert opinion from the european society for blood and marrow transplantation and the american society for blood and marrow transplantation","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0320","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0325","series-title":"Yescarta\u00ae (axicabtagen Ciloleucel) Suspension for IV Infusion: CAR-T Technology-manufacturing Process From the Kite Company","author":"Kite\/Gilead","year":"2020"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0330","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol."},{"issue":"23","key":"10.1016\/j.critrevonc.2020.103096_bib0335","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95103","article-title":"Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy","volume":"2","author":"Klebanoff","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0340","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2020.103096_bib0345","first-page":"504","article-title":"T cells expressing Anti-B-Cell maturation antigen (BCMA) chimeric antigen receptors with antigen recognition domains made up of only single human heavy chain variable domains specifically recognize bcma and eradicate tumors in mice","volume":"130","author":"Lam","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103096_bib0350","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/CJI.0000000000000199","article-title":"Preclinical optimization of a CD20-specific chimeric antigen receptor vector and culture conditions","volume":"41","author":"Lee","year":"2018","journal-title":"J Immunother."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0355","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR t cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0360","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121322","article-title":"4-1BB enhancement of CAR T function requires NF-\u03baB and TRAFs","volume":"3","author":"Li","year":"2018","journal-title":"JCI Insight"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2020.103096_bib0365","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0370","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-018-0212-z","article-title":"TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells","volume":"32","author":"Li","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0375","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2020.103096_bib0380","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1089\/hum.2017.111","article-title":"Automated manufacturing of potent CD20-Directed chimeric antigen receptor t cells for clinical use","volume":"28","author":"Lock","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103096_bib0385","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0390","first-page":"35","article-title":"ZUMA-6: phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (AXI-CEL; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL)","author":"Locke","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0395","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0400","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103096_bib0405","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.critrevonc.2020.103096_bib0410","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103096_bib0415","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0420","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0425","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2016.34.15_suppl.3007","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2020.103096_bib0430","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.2017.35.15_suppl.103","article-title":"The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) Tcells in relapsed acute lymphoblastic leukemia (ALL)","volume":"35","author":"Maude","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2020.103096_bib0435","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V128.22.217.217","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relpased\/refractory acute lymphoblastic leukemia","volume":"128","author":"Maude","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2020.103096_bib0440","first-page":"1319","article-title":"Durable remissions with humanized CD19-Targeted chimeric antigen receptor (CAR)-Modified T-cells in CAR-Naive and CAR-Exposed children and young adults with Relapsed\/Refractory acute lymphoblastic leukemia","volume":"130","author":"Maude","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0445","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0450","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2020.103096_bib0455","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood-2019-129088","article-title":"T cells expressing an Anti-B-Cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-Only antigen recognition domain induce remissions in patients with relapsed multiple myeloma","volume":"134","author":"Mikkilineni","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0460","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcyt.2016.05.009","article-title":"Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy","volume":"18","author":"Mock","year":"2016","journal-title":"Cytotherapy"},{"issue":"24","key":"10.1016\/j.critrevonc.2020.103096_bib0465","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of Tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0470","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2017-05-782888","article-title":"Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy","volume":"130","author":"Nagel","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2020.103096_bib0475","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0480","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2020.103096_bib0485","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2019-126218","article-title":"CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post\u2013Axi-Cel","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0490","series-title":"Fact Sheet: Kymriah\u00ae (tisagenlecleucel) Suspension for Intravenous Infusion","author":"Novartis Pharmaceuticals Corporation US Report Self Cover","year":"2018"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0495","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103096_bib0500","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103096_bib0505","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ymthe.2019.05.015","article-title":"Effect of cryopreservation on autologous chimeric antigen receptor t cell characteristics","volume":"27","author":"Panch","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0510","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0515","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0520","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/bloodadvances.2017011254","article-title":"Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kdelta inhibitors and VIP antagonists","volume":"2","author":"Petersen","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0525","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103096_bib0530","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/asheducation-2018.1.16","article-title":"Are CAR T cells better than antibody or HCT therapy in B-ALL?","volume":"2018","author":"Pulsipher","year":"2018","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"S1","key":"10.1016\/j.critrevonc.2020.103096_bib0535","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1002\/ajh.25399","article-title":"Allogeneic CAR T cell therapies for leukemia","volume":"94","author":"Qasim","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0540","first-page":"9","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103096_bib0545","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2020.103096_bib0550","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood.V130.Suppl_1.810.810","article-title":"Novel CD19\/CD22 bicistronic chimeric antigen receptors outperform single or bivalent cars in eradicating CD19+CD22+, CD19-, and CD22- Pre-B Leukemia","volume":"130","author":"Qin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0555","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncolyt."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0560","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0565","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2018-99-111202","article-title":"CD30-chimeric antigen receptor (CAR) T cells for therapy of hodgkin lymphoma (HL)","volume":"132","author":"Ramos","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2020.103096_bib0570","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR t cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0575","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMp1711886","article-title":"Tragedy, perseverance, and chance\u2014the story of CAR-T therapy","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0580","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0585","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0590","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"issue":"544","key":"10.1016\/j.critrevonc.2020.103096_bib0595","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0600","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/1078-0432.CCR-13-0709","article-title":"EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss","volume":"20","author":"Sampson","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0605","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific t cell dysfunction is a dynamic antigen-driven differentiation program initiated early during Tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0610","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2020.103096_bib0615","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2018-99-117445","article-title":"Phase 1 study of CD19\/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell acute lymphoblastic leukemia (ALL)","volume":"132","author":"Schultz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0620","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor t cells in refractory B-Cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0625","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103096_bib0630","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0635","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0640","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1182\/blood-2018-99-110194","article-title":"A phase 1 study with point-of-care manufacturing of dual targeted, tandem anti-CD19, anti-CD20 chimeric antigen receptor modified T (CAR-T) cells for relapsed, refractory, non-hodgkin lymphoma","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"issue":"Suppl_1","key":"10.1016\/j.critrevonc.2020.103096_bib0645","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1182\/blood-2019-125328","article-title":"Fresh versus Cryopreserved\/Thawed bispecific Anti-CD19\/CD20 CAR-T cells for relapsed, refractory non-hodgkin lymphoma","volume":"134","author":"Shah","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0650","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T cell therapies in diffuse large B cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0655","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1158\/0008-5472.CAN-10-3843","article-title":"Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies","volume":"71","author":"Singh","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103096_bib0660","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/imr.12137","article-title":"A new approach to gene therapy using sleeping Beauty to genetically modify clinical-grade T cells to target CD19","volume":"257","author":"Singh","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0665","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0670","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103096_bib0675","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD81and CD41subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0680","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0685","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"issue":"24","key":"10.1016\/j.critrevonc.2020.103096_bib0690","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246223","article-title":"Optimizing manufacturing protocols of chimeric antigen receptor t cells for improved anticancer immunotherapy","volume":"20","author":"Stock","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0695","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/ijc.32201","article-title":"Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients","volume":"145","author":"Stock","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103096_bib0700","doi-asserted-by":"crossref","DOI":"10.3390\/cells8050472","article-title":"Limitations in the design of chimeric antigen receptors for cancer therapy","volume":"8","author":"Stoiber","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0705","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2386187","article-title":"Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies","author":"Sun","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0710","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/2040620718774268","article-title":"Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?","volume":"9","author":"Tasian","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0715","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4 + :CD8 + composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0720","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0725","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103096_bib0730","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jcyt.2019.10.005","article-title":"Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture","volume":"21","author":"Tyagarajan","year":"2019","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103096_bib0735","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy","volume":"134","author":"van Bruggen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0740","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0745","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcyt.2019.02.013","article-title":"Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells","volume":"21","author":"Wang","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0750","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","article-title":"Expanding the therapeutic window for CAR t cell therapy in solid tumors: the knowns and unknowns of CAR t cell biology","volume":"9","author":"Watanabe","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103096_bib0755","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050674","article-title":"CAR T-Cells targeting the integrin \u03b1v\u03b26 and Co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0760","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103096_bib0765","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"417","key":"10.1016\/j.critrevonc.2020.103096_bib0770","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1209","article-title":"TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance","volume":"9","author":"Yang","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0775","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0780","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24594","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103096_bib0785","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2020.103096_bib0790","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0795","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.103096_bib0800","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1182\/blood-2015-02-628354","article-title":"Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820302328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820302328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:35:15Z","timestamp":1760902515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820302328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":160,"alternative-id":["S1040842820302328"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103096","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103096"}}